title: Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer.
abstract: OBJECTIVE
  This study was undertaken to determine the clinical usefulness of nuclear matrix protein 22 (NMP22) as a novel urine marker for urothelial cancer, particularly, to substitute for voided-urine cytology.
  
  
  METHODS
  NMP22 values were determined for 280 patients and 20 healthy volunteers by NMP22 Test Kit based on an enzyme-linked immunosorbent assay.
  
  
  RESULTS
  When the cut-off value was set at 10 U/ml, the positive rate of urinary NMP22 for urothelial cancer was 80.9% (38/47), whereas that for posttreatment cases and benign diseases was 35.7% (74/207). When urinary NMP22 and voided-urine cytology were compared, the test for urinary NMP22 showed higher sensitivity than cytology in patients with urothelial cancer. When urinary NMP22 values were determined pre- and postoperatively in patients with urothelial cancer, the postoperative value decreased in all patients, and were below the cut-off value in all except one patient.
  
  
  CONCLUSIONS
  Urinary NMP22 is a useful diagnostic marker as a substitute for voided-urine cytology for the surveillance of urothelial cancer.
authors.affiliation: Department of Urology, University of Tsukuba, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Miyanaga
authors.forename: H
authors.initials: H
authors.lastname: Akaza
authors.forename: S
authors.initials: S
authors.lastname: Ishikawa
authors.forename: M
authors.initials: M
authors.lastname: Ohtani
authors.forename: R
authors.initials: R
authors.lastname: Noguchi
authors.forename: K
authors.initials: K
authors.lastname: Kawai
authors.forename: K
authors.initials: K
authors.lastname: Koiso
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: A
authors.initials: A
authors.lastname: Koyama
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000601:surgery / Q000652:urine*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000097:blood / Q000652:urine*; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000601:surgery / Q000652:urine*; D002648:Child; D002940:Circadian Rhythm; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000473:pathology / Q000652:urine; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000097:blood / Q000652:urine*; D010865:Pilot Projects; D012189:Retrospective Studies; D014556:Urine / Q000166:cytology; D014571:Urologic Neoplasms / Q000473:pathology / Q000601:surgery / Q000652:urine*; D019459:Urothelium / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; C100379:nuclear matrix protein 22